Ethotoin

  • 3-Ethyl-5-phenylhydantoin
  • Peganone
Formula
C11H12N2O2
Structure
Description
Stout prisms from water.
Uses
Medication.

Registry Numbers and Inventories.
CAS
86-35-1
EC (EINECS/ELINCS)
201-665-1
RTECS
MU2450000
RTECS class
Drug; Reproductive Effector
Merck
12,3795
Beilstein/Gmelin
188272
Beilstein Reference
5-24-08-00005
Japan ENCS (MITI)
Listed

Properties.
Formula
C11H12N2O2
Formula mass
204.23
Melting point, °C
138
Solubility in water
Insoluble
Partition coefficient, pKow
1.05

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
Ethotoin darkens on exposure to light or extreme heat.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
Cerebellar ataxia, nystagmus, hyperreflexia, drowsiness, lethargy, and coma may occur. Choreoathetosis and dyskinesias have been reported. CNS depression may occur more commonly in children, and ataxia may occur more commonly in adults.
   Inhalation
Severe poisonings may rarely result in respiratory depression.
   Skin
Cutaneous eruptions following phenytoin therapy are common. Purple glove syndrome has been reported following intravenous phenytoin.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Transport.